Randomized trials of venetoclax plus anti-CD20 antibodies as first-line treatment in fit patients (i.e., those with a low burden of coexisting conditions) with advanced chronic lymphocytic leukemia ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback